Betaserk of the tab. of 24 mg No. 20

Tablets "Betaserk ^® " are applied at the following indications:

• a disease and Menyer's syndrome which are characterized by three main symptoms: dizziness which sometimes is followed by nausea and vomiting; decrease in hearing (relative deafness); sonitus;
• symptomatic treatment of vestibular dizziness of various origin.

Structure

Active ingredient - a betagistina dihydrochloride (one tablet supports a betagistin of dihydrochloride of 24 mg).

Excipients: microcrystalline cellulose, attracts (E 421), citric acid monohydrate, silicon dioxide colloidal anhydrous, talc.

Contraindication

• hypersensitivity to active ingredient or to any of medicament excipients;
• pheochromocytoma.

Route of administration

Daily dose for adults makes 24-48 mg, evenly distribute for reception within a day. It is necessary to swallow of tablets, washing down with water.

Tablet on 24 mg - 1 tablet 2 times a day.

Dose should be selected individually, depending on effect. Reduction of symptoms is sometimes observed only after several weeks of treatment. The best results are sometimes achieved at administration of medicament within several months. According to some information, purpose of treatment at the beginning of a disease prevents its progressing or a hearing loss at late stages.

can use Drug irrespective of meal. During intake of this medicine there can be insignificant gastrointestinal disorders which can be eliminated by administration of medicament together with food.

Feature of use

Pregnant women

Are not present sufficient data concerning use of a betagistin to pregnant women. Betagistin it is not necessary to apply during pregnancy, except for emergency cases.

whether gets betagistin into breast milk of the person. The advantage of use of medicament for mother should be correlated to advantages of feeding by a breast and potential risk for the child.

Research on rats were not revealed by influences on fertility.

Due to the insufficiency of data on safety and efficiency of use of this medicament children are not recommended to appoint

(aged up to 18 years).

Drivers

by

for treatment of a syndrome of Menyer that is characterized by a triad of the main symptoms: dizziness, decrease in hearing, sonitus and also for symptomatic treatment of vestibular dizziness. Both states can have negative effect on ability to drive the car and to work with mechanisms. According to the clinical trials studying influence on ability to drive the car and to work with other mechanisms, betagistin did not influence or had insignificant influence on this ability.

to

Overdose

Knows several cases of overdose of drug. At some patients easy and moderate symptoms (nausea, drowsiness, an abdominal pain) after administration of medicament in a dose up to 640 mg were observed. More serious complications (spasms, cardiopulmonary complications) were observed at intended reception of the raised doses of a betagistin, especially in combination with overdose of other medicines.

Treatment of overdose has to include the standard supporting actions.

side Below-mentioned reactions were observed by

at the patients receiving this medicament during placebo - controlled researches.

from digestive tract: frequent (≥ 1/100 to <1/10) - nausea and dyspepsia.

from nervous system: frequent (≥ 1/100 to <1/10) - a headache.

Storage conditions

to Store

in original packing at a temperature not above 25 °C, out of children's reach.

Expiration date - 5 years.